SCHEMBL1261911

SCHEMBL1261911

CC1CCN(C(=O)O)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
NPC1 O15118 3/20 0.56
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
ACHE P22303 1/20 0.53
GAA P10253 1/20 0.48
PHGDH O43175 1/20 0.48
MGLL Q99685 1/20 0.48
GRM5 P41594 1/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
USP2 O75604 1/20 0.42
RAB9A P51151 2/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28221817 0.97 ALDH1A1 (0.54) ALDH1A1NPC1KMT2AMEN1ACHE
SCHEMBL18949269 0.87 KDM4E (0.56) ALDH1A1NPC1KMT2AMEN1ACHE
SCHEMBL3409523 0.85
SCHEMBL6037523 0.85
Hydrochloric Acid SCHEMBL28226357 0.83 ALDH1A1 (0.45) ALDH1A1NPC1KMT2AMEN1ACHE
SCHEMBL10280128 0.82 ALDH1A1 (0.54) ALDH1A1NPC1KMT2AMEN1ACHE
SCHEMBL25446918 0.81 ALDH1A1 (0.58) ALDH1A1NPC1KMT2AMEN1ACHE
Chlorobenzene SCHEMBL27699522 0.81 ACHE (0.60) ALDH1A1NPC1KMT2AMEN1ACHE
Fluorobenzene SCHEMBL27670265 0.81 ACHE (0.60) ALDH1A1NPC1KMT2AMEN1ACHE
SCHEMBL27183 0.79 ALDH1A1 (0.56) ALDH1A1NPC1KMT2AMEN1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors NIKANG THERAPEUTICS, INC. (US) 2025-06-17 US claimed
US-20230303509-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. 2023-09-28 US claimed
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 EP claimed
EP-3661941-B1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 EP claimed
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 US claimed
CN-115109250-A Macromolecular material containing amphiphilic group, preparation method and application thereof 上海大学 2022-09-27 CN claimed
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2022-09-27 US claimed
US-11186592-B2 Thiazolopyridine derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2021-11-30 US claimed
US-20200207720-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2020-07-02 US claimed
EP-3672952-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS Merck Patent GmbH (DE) 2020-07-01 EP claimed
CN-101119717-A Substituted phenols as agents inhibiting VEGF production PTC THERAPEUTICS INC (US) 2008-02-06 CN claimed
US-7317007-B2 Benzothiazole derivatives with activity as adenosine receptor ligands HOFFMANN-LA ROCHE INC. (US) 2008-01-08 US claimed
WO-2007137955-A1 PIPERIDINYL PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO claimed
US-20070281921-A1 Piperidinyl pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2007-12-06 US claimed
CN-101080392-A Piperazinyl pyridine derivatives as anti-obesity agents HOFFMANN LA ROCHE (CH) 2007-11-28 CN claimed
EP-1828134-A1 PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-09-05 EP claimed
US-20060135528-A1 Piperazinyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2006-06-22 US claimed
WO-2006063718-A1 PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-06-22 WO claimed
US-20060003986-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ALANINE ALEXANDER 2006-01-05 US claimed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060003986-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 ALDH1A1 383/4885NPC1 1587/4885KMT2A 3263/4885
US-20060135528-A1 Piperazinyl-pyridine derivatives HRH4, HRH3, H1-3 ALDH1A1 814/4885NPC1 1029/4885KMT2A 409/4885
US-20070281921-A1 Piperidinyl pyrimidine derivatives HRH2, P2RX5, P2RX3 ALDH1A1 1692/4885NPC1 1763/4885KMT2A 1101/4885
US-20230303509-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS CDK2, CCNK, CCNI ALDH1A1 3620/4885NPC1 4479/4885KMT2A 905/4885
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ALDH1A1 1065/4885NPC1 1078/4885KMT2A 2269/4885
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors CDK2, CCNK, CCNI ALDH1A1 3620/4885NPC1 4479/4885KMT2A 905/4885
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ALDH1A1 617/4885NPC1 1208/4885KMT2A 3289/4885
US-11186592-B2 Thiazolopyridine derivatives as adenosine receptor antagonists ADORA1, ADORA2A, AMPD2 ALDH1A1 585/4885NPC1 685/4885KMT2A 3978/4885
US-20200207720-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ALDH1A1 1065/4885NPC1 1078/4885KMT2A 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.